Opinion|Videos|November 20, 2026

Efficacy of CAR T-Cell Therapy in Relapsed/Refractory CLL

Dr. Jennifer J. Huang and Dr. Mazyar Shadman review findings from the TRANSCEND CLL004 study evaluating lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

Dr. Jennifer J. Huang and Dr. Mazyar Shadman review findings from the TRANSCEND CLL004 study evaluating lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Dr. Huang explains that the study provided an additional treatment option for patients with CLL, although the complete response rate with liso-cel monotherapy was approximately 20%. She discusses the rationale for combining Bruton tyrosine kinase (BTK) inhibition with CAR T-cell therapy, including the potential to reduce CAR T-cell exhaustion. The experts highlight findings from a separate cohort in which liso-cel was administered with ibrutinib, with the complete response rate increasing from approximately 20% to 40%. Dr. Shadman notes that patients in the combination cohort had previously experienced disease progression on ibrutinib, raising interest in the potential contribution of continued BTK inhibition alongside CAR T-cell therapy. They also acknowledge that these findings came from separate, nonrandomized cohorts with limited patient numbers and may not directly translate to current practice, where patients may receive other BTK inhibitors, including pirtobrutinib.


Related to this article